These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27481010)

  • 1. Liquid Biopsies for Assessing Metastatic Melanoma Progression.
    Huynh K; Hoon DS
    Crit Rev Oncog; 2016; 21(1-2):141-54. PubMed ID: 27481010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
    Busser B; Lupo J; Sancey L; Mouret S; Faure P; Plumas J; Chaperot L; Leccia MT; Coll JL; Hurbin A; Hainaut P; Charles J
    Biomed Res Int; 2017; 2017():5986129. PubMed ID: 28484715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
    Xu MJ; Dorsey JF; Amaravadi R; Karakousis G; Simone CB; Xu X; Xu W; Carpenter EL; Schuchter L; Kao GD
    Oncologist; 2016 Jan; 21(1):84-94. PubMed ID: 26614709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
    Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
    Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A headlight on liquid biopsies: a challenging tool for breast cancer management.
    Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
    Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dynamic range of circulating tumor DNA in metastatic breast cancer.
    Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
    Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
    Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
    Parimi S; Ko JJ
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer.
    Gao Y; Zhu Y; Yuan Z
    Int J Med Sci; 2016; 13(12):902-913. PubMed ID: 27994495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the Cancer Genome in Blood.
    Dawson SJ
    Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29844219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
    Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
    Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.